Collagen News and Research

Latest Collagen News and Research

FDA Advisory Committee recommends marketing approval for Auxilium's XIAFLEX to treat Dupuytren's contracture

Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the Arthritis Advisory Committee appointed by the U.S. Food and Drug Administration (FDA) recommended by a unanimous vote of 12 to 0 that XIAFLEX™ (collagenase clostridium histolyticum), a novel, first-in-class, orphan-designated, biologic, be granted marketing approval by the FDA for the treatment of Dupuytren's contracture.

17 Sep 2009

BioSpecifics Technologies' XIAFLEX receives marketing approval from FDA

BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first-in-class collagenase-based products, today announced that the Arthritis Advisory Committee appointed by the U.S.

17 Sep 2009

GENova in advanced negotiations to acquire patents from TheraGlass

GENova Biotherapeutics Inc. ("GENova") is pleased to announce that it is in advanced negotiations to acquire a number of patents from TheraGlass Ltd., a company that produces a ground-breaking regenerative bioactive material with exciting potential applications.

16 Sep 2009

PhotoMedex unveils Neova DNA Repair Factor Nourishing Lotion

PhotoMedex, Inc., a leading provider of advanced dermatology, clinical skincare and medical laser products, today announced Neova DNA Repair Factor Nourishing Lotion, the newest addition to its renowned Neova brand of skin and hair products.

16 Sep 2009

Cardium's Gene Activated Matrix technology demonstrates benefits in periodontal tissue regeneration

Cardium Therapeutics (NYSE Amex: CXM) today reported on preclinical findings published in the scientific journal, Gene Therapy, demonstrating that Cardium's Gene Activated Matrix(TM) or GAM(TM) technology accelerates periodontal tissue regeneration of oral implant-supporting wounds.

15 Sep 2009

Stimulating effect of bioactive collagen peptides in cell experiments demonstrated

Working in collaboration with Kiel University, researchers at the Kiel- based Collagen Research Institute (CRI) have demonstrated the stimulating effect of special bioactive collagen peptides (FORTIGEL(R)) in the context of cell experiments. Last weekend the CRI presented its research findings at the congress of the Osteoarthritis Research Society International (OARSI) in Montreal.

15 Sep 2009

Positive results from Merck's Phase IIB clinical study of odanacatib for treating osteoporosis

New data from a Phase IIB clinical study of odanacatib, Merck & Co., Inc.'s oral, once-weekly investigational treatment for osteoporosis, showed that when stopping treatment after two years, the increases in lower back (lumbar spine) bone mineral density (BMD) were reversed over the next year, while BMD at the hip (femoral neck) remained above levels observed at the start of the study.

15 Sep 2009

Clinical studies reveal treatment with pirfenidone is safe and well-tolerated

InterMune, Inc. (Nasdaq: ITMN) today announced that the results of a comprehensive review of safety data from four clinical studies were presented at the 2009 European Respiratory Society Annual Congress in Vienna, Austria by Dr. Ulrich Costabel of the Ruhrlandklinik, Essen, Germany.

14 Sep 2009

Acceleron's Phase 1 trial of ACE-031 reveals its potential in treating neuromuscular diseases

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, and muscle, today announced preliminary results from the ACE-031 Phase 1 single dose clinical trial demonstrating that ACE-031 increased lean body mass and muscle volume. The results from this randomized, placebo-controlled study were presented at the 14th International Congress of the World Muscle Society in Geneva, Switzerland.

10 Sep 2009

Virginia Tech wins National Science Foundation grant to study knee ligament sprains

A team of Virginia Tech engineering researchers has won a $300,000 National Science Foundation grant to study knee ligament sprains at the micro-mechanical level.

10 Sep 2009

Galapagos starts new clinical trial for GLPG0259

Galapagos NV (Euronext: GLPG) announced today that it has initiated a second Phase I clinical trial for GLPG0259, a novel candidate drug being developed for rheumatoid arthritis (RA).

10 Sep 2009

Clinical trial reveals RENOVA topical treatment cream shows continuous improvement

In 2008, the global anti-aging skincare market approached $15 billion, with 32 percent of U.S. facial skincare product launches boasting anti-aging claims many over-the-counter products are claiming to achieve comparable benefits as prescription anti-aging treatments.

10 Sep 2009

Defective chemical bond in biological tissue may be the reason for diseases, say researchers

Researchers at Vanderbilt University Medical Center led by Billy Hudson, Ph.D., have discovered a new chemical bond in biological tissue, a fundamental discovery that helps explain evolutionary adaptation in the animal kingdom and may shed light on human disease.

4 Sep 2009

Phase III clinical trial results of XIAFLEX published in a journal

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products today announced results of the pivotal CORD I Phase III clinical trial of XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class biologic for the nonsurgical treatment of Dupuytren's disease, was published in today's edition of the New England Journal of Medicine.

4 Sep 2009

Consumers seek functional foods and supplements to enhance wellness quotient

An expanding aging population and increased consumer awareness boosts growth for the U.S. bone and joint health ingredients market. Consumers increasingly seek supplements and functional foods that enhance their wellness quotient and have strong scientific backup.

3 Sep 2009

Ethical Alternative Products launches the OmniFlex joint support formula

Ethical Alternative Products has launched OmniFlex, a unique joint support formula combining five highly researched ingredients shown specifically to positively impact joint structure and function in easy-to-swallow soft-gel capsules.

3 Sep 2009

CORD I phase III clinical trial results of XIAFLEX published

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that The New England Journal of Medicine (NEJM) has published in its September 3rd edition, the Company's pivotal CORD I Phase III clinical trial of XIAFLEX (collagenase clostridium histolyticum) a novel, first-in-class, biologic for the nonsurgical treatment of Dupuytren's contracture.

3 Sep 2009

New method for treating hand disorder discovered

Researchers in the Department of Orthopaedics at Stony Brook University Medical Center have developed an injectable form of the enzyme, collagenase, that significantly improves outcomes of Dupuytren's contracture (or disease), a debilitating disorder caused by progressive accumulation of collagen that deforms fingers and limits motion. Reported in September 3, 2009, issue of The New England Journal of Medicine, the study involved treatment of 308 patients with Duputren's disease in 16 sites nationwide. The results indicate that the injections are safe and effective.

3 Sep 2009

Third-quarter fiscal 2009 results announced by Synovis Life Technologies

Synovis Life Technologies Reports Record Revenue Of $15 Million For The Third Quarter Of Fiscal 2009

2 Sep 2009

Covalon Technologies announces fiscal 2009 third-quarter results

Covalon Technologies Ltd. (TSX VENTURE:COV) announces the release of its financial statements for the third quarter of fiscal 2009 ending June 30, 2009. Revenues from product sales, coating services and licensing fees for the three months ended June 30, 2009 were $401,837, an increase of $64,575 over the same period in the previous year.

28 Aug 2009

Collagen News and Research

Latest Collagen News and Research

FDA Advisory Committee recommends marketing approval for Auxilium's XIAFLEX to treat Dupuytren's contracture

BioSpecifics Technologies' XIAFLEX receives marketing approval from FDA

GENova in advanced negotiations to acquire patents from TheraGlass

PhotoMedex unveils Neova DNA Repair Factor Nourishing Lotion

Cardium's Gene Activated Matrix technology demonstrates benefits in periodontal tissue regeneration

Stimulating effect of bioactive collagen peptides in cell experiments demonstrated

Positive results from Merck's Phase IIB clinical study of odanacatib for treating osteoporosis

Clinical studies reveal treatment with pirfenidone is safe and well-tolerated

Acceleron's Phase 1 trial of ACE-031 reveals its potential in treating neuromuscular diseases

Virginia Tech wins National Science Foundation grant to study knee ligament sprains

Galapagos starts new clinical trial for GLPG0259

Clinical trial reveals RENOVA topical treatment cream shows continuous improvement

Defective chemical bond in biological tissue may be the reason for diseases, say researchers

Phase III clinical trial results of XIAFLEX published in a journal

Consumers seek functional foods and supplements to enhance wellness quotient

Ethical Alternative Products launches the OmniFlex joint support formula

CORD I phase III clinical trial results of XIAFLEX published

New method for treating hand disorder discovered

Third-quarter fiscal 2009 results announced by Synovis Life Technologies

Covalon Technologies announces fiscal 2009 third-quarter results

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Collagen News and Research

Latest Collagen News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in